HC Wainwright Comments on Scholar Rock Q1 Earnings

Posted by Geri Gentry on Nov 11th, 2026

Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Scholar Rock in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.76) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Scholar Rock’s Q2 2027 earnings at ($0.71) EPS, Q3 2027 earnings at ($0.64) EPS and Q4 2027 earnings at ($0.55) EPS.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. The business had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the prior year, the business posted ($0.90) EPS.

A number of other brokerages have also issued reports on SRRK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, October 15th. Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 price objective on shares of Scholar Rock in a research report on Monday, September 21st. Citigroup boosted their target price on shares of Scholar Rock from $60.00 to $74.00 and gave the stock a “buy” rating in a report on Monday, September 14th. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. Finally, Barclays cut shares of Scholar Rock from an “overweight” rating to a “cautious” rating in a research note on Tuesday, September 15th. Four analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $67.67.

View Our Latest Stock Analysis on SRRK

Scholar Rock Stock Down 6.9%

NASDAQ SRRK opened at $48.00 on Wednesday. The stock’s 50 day moving average is $46.83 and its 200 day moving average is $48.22. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77. Scholar Rock has a 12 month low of $28.97 and a 12 month high of $61.76. The stock has a market cap of $5.85 billion, a PE ratio of -13.91 and a beta of 0.78.

Insider Activity at Scholar Rock

In other news, Director Srinivas Akkaraju purchased 146,970 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The stock was bought at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the purchase, the director owned 6,380,517 shares in the company, valued at approximately $265,365,702.03. This represents a 2.36% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of Scholar Rock

A number of large investors have recently added to or reduced their stakes in SRRK. GW&K Investment Management LLC purchased a new position in shares of Scholar Rock in the third quarter valued at $17,534,000. Voya Investment Management LLC increased its position in Scholar Rock by 4.8% in the third quarter. Voya Investment Management LLC now owns 933,359 shares of the company’s stock worth $45,100,000 after purchasing an additional 42,752 shares during the last quarter. Public Sector Pension Investment Board purchased a new stake in Scholar Rock during the third quarter valued at $3,044,000. Russell Investments Group Ltd. raised its stake in Scholar Rock by 7.5% during the third quarter. Russell Investments Group Ltd. now owns 140,270 shares of the company’s stock valued at $6,778,000 after purchasing an additional 9,756 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. raised its stake in Scholar Rock by 164.9% during the third quarter. Nan Fung Trinity HK Ltd. now owns 264,695 shares of the company’s stock valued at $12,790,000 after purchasing an additional 164,776 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock News Roundup

Here are the key news stories impacting Scholar Rock this week:

Positive Sentiment: Scholar Rock reported a Q3 loss of $0.81 per share, beating estimates of $0.85–$0.87, and revenue of $0.57 million, above the $0.30 million forecast. The quarter included the company’s first product revenue, a milestone that may support investor optimism about commercialization. Q3 results Company results and business highlights
Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 target. Its 2027 quarterly estimates project progressively smaller losses, from $0.76 per share in Q1 to $0.55 in Q4. Analyst coverage
Negative Sentiment: Despite the earnings beat and new product revenue, Scholar Rock remains loss-making; HC Wainwright’s estimates still show quarterly losses throughout 2027. This keeps execution and future commercialization important considerations for investors.

About Scholar Rock

(Get Free Report)

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.